Budget review: Here’s what ASX biotech players thought of the ‘patent box’
he federal government’s “patent box” initiative caught the eye of Australia’s biotech sector in Tuesday...
he federal government’s “patent box” initiative caught the eye of Australia’s biotech sector in Tuesday...
Prescient Therapeutics (ASX:PTX) has announced a new research program with the Peter MacCallum Cancer Centre...
Prescient Therapeutics Ltd (ASX:PTX) has signed an agreement related to advancing a new research program with...
Prescient Therapeutics (PTX) has announced a new research program with the Peter MacCallum Cancer Centre...
Biotech company Prescient Therapeutics (ASX:PTX) had an important announcement for the market this morning, after strengthening its...
Prescient Therapeutics has inked a new deal with leading research organisation Peter MacCallum Cancer Centre...
With the number of days left to file March quarterly reports running a little short...
Melbourne biotech company Prescient Therapeutics (ASX:PTX) says a clinical trial evaluating its PTX-200 drug candidate to treat...
Prescient Therapeutics (PTX) will progress to the next dose level of its Phase 1b clinical...
The market for revolutionary CAR-T cancer treatments is expected to grow to USD 14 billion...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.